World Metastatic Colorectal Cancer Day: Improving our understanding of BRAFV600E-mutant mCRC patients through RWD

Worldwide, colorectal cancer (CRC) is the third most common type of cancer in men and the

second most common in women, with approximately 1.9 million new diagnoses in 2020. Globally

in 2020, approximately 935,000 deaths were attributed to CRC.¹ BRAF mutations are estimated to occur in approximately 8–12% of patients with mCRC^2-8 and confer a poor prognosis to these patients.^9.10 The V600E mutation is the most common BRAF mutation^11,12

Today, on World Metastatic Colorectal Cancer (mCRC) Day, we are sharing the results of our CAPSTAN CRC study - our latest real-world evidence study in mCRC aimed to better understand the current treatment practices for this patient population in everyday clinical practice. The study provided more insights and important information about BRAF^V600E-mutant mCRC – a form of mCRC with a particularly poor prognosis. 

Watch this short video of Prof Dirk Arnold (Head of Oncology, Haematology & Palliative Care, AK Altona, Hamburg and Director, Asklepios Tumorzentrum, Hamburg) to find out his perspectives on what the CAPSTAN study has shown and why these findings are important for patients diagnosed with BRAF^V600E-mutant mCRC. 

With 66% of patients in this study diagnosed with BRAFV600E-mutant colorectal cancer at a late-stage when the cancer had spread to other parts of the body, and only half of patients able to go on and receive second line therapy,¹³ these findings reinforce the importance of continuing to support research and gather data to better understand and appropriately treat this aggressive disease. 

Further, the study highlighted the critical need for earlier initiation of therapy and for more innovative first-line treatment strategies for these patients.

Pierre Fabre is committed to supporting patients with mCRC and continuing out research into this disease.

About the CAPSTAN study

CAPSTAN is the largest database of patients with BRAF^V600E-mutant metastatic colorectal cancer. The CAPSTAN CRC study is a retrospective, longitudinal study which aims to characterize first-line treatment patterns of BRAF^V600E-mutant mCRC patients in the real-world setting.

 

Patient data was collected from 34 medical centres in 7 European countries. In total 255 patients took part, who had received first line treatment between 2016 and 2018.

References

1.    The Global Cancer Observatory, 2020. International Agency for Research on Cancer, World Health Organization. Available at: https://gco.iarc.fr/today/online-analysis-multi-bars. Accessed September 2021.

2.    Maughan TS, et al. Lancet. 2011;377:2103–14.

3.    Souglakos J, et al. Br J Cancer. 2009;101:465–72.

4.    Richman SD, et al. J Clin Oncol. 2009;27:5931–7.

5.    Tran B, et al. Cancer. 2011;117:4623–32.

6.    Tie J, et al. Int J Cancer. 2011;128:2075–84.

7.    Tviet KM, et al. J Clin Oncol. 2012;30:1755–62.

8.    Vecchione L, et al. Cell. 2016;165:317–30.

9.    Van Cutsem E, et al. Ann Oncol. 2016;27(8):1386–1422.

10.    Kopetz S, et al. NEJM. 2019;381(17):1632-1643.

11.    Sclafani F, et al. Crit Rev Oncol Hematol. 2013;87:55–68.

12.    Safaee Ardekani G, et al. PLoS One. 2012;7:e47054.

13.    Asselain B, et al. First-line treatment patterns in BRAFV600E-mutant metastatic colorectal cancer patients (mCRC): The CAPSTAN CRC European retrospective study. Ann Oncol. 2021;32:P438.